Piramal Pharma Profile
Key Indicators
- Authorised Capital ₹ 3,000.00 Cr
- Paid Up Capital ₹ 1,325.75 Cr
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1,480.00 Cr
- Satisfied Charges ₹ 1,000.00 Cr
- Revenue Growth 14.03%
- Profit Growth -79.74%
- Ebitda -75.45%
- Net Worth 3.84%
- Total Assets 11.57%
About Piramal Pharma
Piramal Pharma Limited (PPL) is a Public Limited Indian Non-Government Company incorporated in India on 04 March 2020 (Four years and 11 months 18 days old ). Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 543635.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3,000.00 Cr and a paid-up capital of Rs 1,325.75 Cr.
The company currently has active open charges totaling ₹1,480.00 Cr. The company has closed loans amounting to ₹1,000.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Piramal Pharma Limited India are Vivek Valsaraj as CFO and Tanya Dcosta as Company Secretary. Ramadorai Subramanian, Sridhar Gorthi, Jairaj Purandare, and Six other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24297MH2020PLC338592
- Company No.
338592
- Stock Symbol
BSE : 543635
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2020
- Date of AGM
31 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Piramal Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Valsaraj  | CFO | 09-Feb-2021 | Current |
| Tanya Dcosta | Company Secretary | 10-Sep-2020 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Peter Stevenson  | Director | 30-Mar-2022 | Current |
| Peter Deyoung | Whole-Time Director | 04-Mar-2020 | Current |
| Jairaj Purandare | Director | 09-Feb-2021 | Current |
| Ramadorai Subramanian | Director | 09-Feb-2021 | Current |
| Sridhar Gorthi | Director | 30-Mar-2022 | Current |
| Nandini Piramal | Whole-Time Director | 04-Mar-2020 | Current |
Financial Performance of Piramal Pharma.
Piramal Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.03% increase. The company also saw a substantial fall in profitability, with a 79.74% decrease in profit. The company's net worth moved up by a moderate rise of 3.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Piramal Pharma?
In 2023, Piramal Pharma had a promoter holding of 34.79% and a public holding of 65.22%. The company had 1 Subsidiary and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nxtra Data LimitedNeeraj Bharadwaj is a mutual person
Icici Prudential Life Insurance Company LimitedVibha Rishi is a mutual person
Carlyle India Advisors Private LimitedNeeraj Bharadwaj is a mutual person
Foundation For Promotion Of Sports And GamesNeeraj Bharadwaj is a mutual person
Piramal Water Private LimitedNandini Piramal is a mutual person
Exide Industries LimitedSridhar Gorthi is a mutual person
Charges (Loans)
₹1,480.00 Cr
₹1,000.00 Cr
Charges Breakdown by Lending Institutions
- Idbi Trusteeship Services Limited : 730.00 Cr
- Others : 350.00 Cr
- The Hongkong And Shanghai Banking Corporation Limited : 300.00 Cr
- Standard Chartered Bank : 50.00 Cr
- Citi Bank N.A. : 50.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Feb 2024 | Idbi Trusteeship Services Limited | ₹200.00 Cr | Open |
| 18 Dec 2023 | Idbi Trusteeship Services Limited | ₹130.00 Cr | Open |
| 24 May 2023 | Idbi Trusteeship Services Limited | ₹300.00 Cr | Open |
| 16 Mar 2023 | The Hongkong And Shanghai Banking Corporation Limited | ₹200.00 Cr | Open |
| 03 Mar 2023 | The Hongkong And Shanghai Banking Corporation Limited | ₹100.00 Cr | Open |
How Many Employees Work at Piramal Pharma?
Piramal Pharma has a workforce of 3851 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Piramal Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Piramal Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
